Xenios announced in late November that it had received CE mark for i-cor, an acute mechanical circulatory support device that provides assistance to a failing heart with an external, heartbeat-synchronized system that generates an artificial pulse. The company believes i-cor will open up new therapy options for the hundreds of thousands of patients in acute heart failure (cardiogenic shock) and in those undergoing high-risk interventions in the cath lab – a market opportunity estimated at $5 billion annually in the US and Europe alone.
In late November, German-based Xenios AG announced that it had received CE mark for the world’s first heartbeat-synchronized cardiac-assist system. i-cor generates an artificial pulse via a blood pump that is triggered by an electrocardiogram (ECG) signal. The pulse, in turn, “overlays” a physiological pulse wave onto the patient’s weakened pulse.
“i-cor has been designed to overcome limitations of cardiac assist in the past by linking it more closely to the...